MR001

· Shenzhen Majory Biotechnology Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for MR001, covering 2025-12-31 to 2026-02-12. Get the full timeline:

Most recent: Clinical Trial Update: A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC) [Phase 1, Phase 2]

See pricing